Over the past 18 months, the flunisolide 2029 industry trends have pivoted toward sustainability-driven reformulation and digital therapeutics integration. In March 2024, Cipla acquired a 26 % stake in PulmoTech AI, gaining access to machine-learning-driven inhaler adherence analytics that will be layered onto next-gen flunisolide combos. Europe’s January 2024 regulatory pivot—switching flunisolide MDIs to low-GWP propellants—has accelerated Hikma and Chiesi’s joint venture for a hydrofluoro-olefin-powered device, now in Phase III. Meanwhile, AstraZeneca’s November 2023 partnership with Verity Pharma is piloting a recyclable Respimat-style platform, targeting 30 % plastic reduction before 2027. Patient-centric demand for propellant-free options lifted breath-actuated dry-powder flunisolide scripts by 12 % YoY in the U.S., prompting Vectura to raise $88 m in Series C funding (April 2024) to scale porous-particle engineering. Finally, China’s July 2023 inclusion of flunisolide in its innovation reimbursement list is forecast to add 4.3 m treated patients annually, reshaping volume forecasts for the 2029 horizon.
